Navigation Links
Sinovac's Credit Rating Upgraded to AAZ, Second Highest Rating
Date:10/9/2008

Obtains 10 Million RMB Commercial Bank Loan With Interest Payment Subsidy

BEIJING, Oct. 9 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that the Beijing Zhongguancun Enterprises Credit Promotion Association at the Zhongguancun Science and Technology Park organized an annual Business Credit Rating program. As part of that program, Sinovac Biotech Co. Ltd.'s ("the Company") credit rating was successfully upgraded to AAzc, the second-highest level, from Azc, the third-highest level of nine levels. This available additional capital ensures the Company's expansion of production scale and satisfies the capital demand of its business development strategy. Sinovac's financial department is in active communication with the Zhongguancun Guarantee Company and increased the amount of credit guarantee. Meanwhile, the department is extending cooperation to other banks. Recently, the Company obtained 10 million RMB guaranteed loan from China Merchants Bank Shangdi Branch, which has a solid reputation in China and internationally.

Sinovac has established good credit with the Haidian Science Park of Zhongguancun Science and Technology Garden Zone and with the Regulatory Committees (or Haidian Park), which will subsidize 40% of the interest payment for the above mentioned bank loan, which is the highest standard in the area.

Mr. Weidong Yin, President and CEO, commented, "As the U.S. financial crisis spreads to the global markets, Sinovac will maintain its various capital raising opportunities through its established track record and reputation built in China. No matter how volatile the global financial market is, we will keep executing our expansion strategy. Both credit rating upgrade and bank loans will ensure capital raising sources for business development. Management is confident in the future of the company."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington / Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
2. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
3. AviaraDx Announces CAP Accreditation of Its Laboratory Operations
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
6. Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements
7. Credit-card-sized platform for volatile compound analysis CAREER project goal
8. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
9. GeneNews receives ISO 13485 accreditation
10. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
11. Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... ... its GMP cell therapy manufacturing facility at its headquarters laboratory in Poway, California. ... and utilizing the experience of both in-house personnel and consultants, VetStem constructed and ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017 /PRNewswire/ ... that apatorsen results from two randomized Phase 2 clinical trials ... 2017 Genitourinary Cancers Symposium, held February 16 th - 18 ... from trials in bladder and prostate cancers demonstrated apatorsen was ... standard-of-care treatments. ...
(Date:2/21/2017)... 21, 2017   Logicalis Healthcare Solutions , the ... and managed services provider ( www.us.logicalis.com ), today announced ... Epic. The new service will help hospital CIOs make ... giving physicians, nurses and other clinicians immediate access to ... This will allow hospital IT staff to focus on ...
(Date:2/21/2017)... , Feb. 21, 2017   Invitae Corporation ... information companies, today announced that members of the company,s ... 37th Annual Health Care Conference on Monday, March 6, ... Pacific in Boston, Massachusetts . ... may be accessed by visiting the investors section of ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... The global synthetic-biology market ... billion by 2021, growing at a compound annual growth rate ... overview of the global markets for synthetic biology. - Analyses ... 2016, and projections of compound annual growth rates (CAGRs) through ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology News(10 mins):